Rose-hip powder seemed to have a small to moderate effect on pain in osteoarthritis patients and may be of interest as a herbal remedy. Further research in a large, long-term trial was needed to substantiate these results. Given the small number of trials and participants, as well as the loss of data through only including the first phase of crossover trials, the authors' conclusion may not be reliable.
Authors' objectives
To determine the efficacy of hip powder Rosa canina (rose-hip) as a pain reducing compound for the symptomatic treatment of osteoarthritis.
Searching
MEDLINE, EMBASE, CINAHL, BIOSIS Previews, Web of Science, SciFinder, Scopus and the Cochrane Library were searched without language restriction up to October 2007. Search terms were reported. Reference lists of relevant articles and conference abstracts (over the last two years) from established international societies of rheumatology were also checked.
Study selection
Randomised controlled trials (RCTs) comparing a preparation of rose-hip powder with placebo in patients with clinical or radiographic evidence of osteoarthritis were eligible for inclusion in the review. The primary outcome of interest was reduction in pain. Secondary outcome included change in the average level of painkillers used, the number of responders to therapy and adverse events. Studies in conditions such as non-osteoarthritis joint pain, rheumatoid arthritis, pain due to surgery or injury or studies with mixed patient groups (e.g., osteoarthritis and rheumatoid arthritis) unless subgroup data for osteoarthritis were available, were excluded.
The intervention in all the trials included rose-hip powder 5g/day and mean trial duration was 3.3 months. All included participants were selected from outpatient clinics. One trial included osteoarthritis patients who had experienced pain for at least six months and who were on a waiting list for either hip or knee surgery or on a list for final evaluation for surgery. Most participants were women (62%) suffering from knee osteoarthritis (61%); other joints affected included neck and hand osteoarthritis. Participants had a median age of 65.6 years and, where reported, mean body mass index ranged from 27.0 to 27.3kg/m 2 . One trial was conducted in Norway and two trials were conducted in Denmark.
Two reviewers selected and reached agreement on studies for inclusion in the review.
Assessment of study quality
The quality of the studies was assessed using the Jadad scale, with the following criteria: reported randomisation, masking, and withdrawals. A maximum of five points could be awarded.
Two reviewers assessed the studies for quality.
Data extraction
The number of responders to therapy was extracted for each study. Mean differences with standard deviations were calculated for continuous outcomes and odd ratios (ORs) with 95% confidence intervals (CIs) for dichotomous outcomes.
Two reviewers independently extracted data using a customised form and any disagreements were resolved through consensus.
